Summary
IDEXX Laboratories Inc. reported strong financial results for the third quarter and first nine months of 2019, demonstrating robust revenue growth and improved profitability. Revenue increased by 11.0% for the third quarter and 8.3% for the nine-month period, driven primarily by the Companion Animal Group (CAG) segment, which saw significant growth in recurring revenue streams like consumables and reference laboratory services. The company maintained healthy gross profit margins, benefiting from increased sales volumes, price increases, and favorable product mix, particularly within the CAG segment. Operating expenses also grew, largely due to strategic investments in sales and marketing to expand the global commercial infrastructure and in research and development. Despite these investments, operating income saw a substantial increase of 19.1% in the third quarter and 16.3% for the nine-month period, reflecting the company's ability to scale its operations effectively. IDEXX continues to manage its balance sheet prudently, with sufficient cash and cash equivalents and available borrowing capacity. The company also made progress in adopting new accounting standards, notably the New Leasing Standard, which impacted its balance sheet by recognizing operating lease liabilities and right-of-use assets. Overall, the financial performance indicates a strong operational execution and a positive outlook for the company.
Financial Highlights
52 data points| Revenue | $605.30M |
| Cost of Revenue | $260.35M |
| Gross Profit | $344.95M |
| R&D Expenses | $34.26M |
| Operating Income | $139.80M |
| Interest Expense | $7.09M |
| Net Income | $108.84M |
| EPS (Basic) | $1.26 |
| EPS (Diluted) | $1.24 |
| Shares Outstanding (Basic) | 86.20M |
| Shares Outstanding (Diluted) | 87.67M |
Key Highlights
- 1Total revenue for the third quarter increased by 11.0% to $605.3 million, and for the first nine months by 8.3% to $1.8 billion, driven by strong performance across segments.
- 2Companion Animal Group (CAG) revenue grew 11.5% in Q3 and 9.1% year-to-date, with significant contributions from IDEXX VetLab consumables and reference laboratory diagnostic services.
- 3Gross profit margin improved by 100 basis points to 57.0% in Q3, reflecting higher sales volumes, price increases, and favorable product mix.
- 4Income from operations increased by 19.1% to $139.8 million for the third quarter, showcasing strong operational leverage.
- 5The company adopted the new Leases standard (ASC 842) on January 1, 2019, resulting in the recognition of operating lease liabilities and right-of-use assets.
- 6Cash provided by operating activities increased by 14.8% to $303.7 million for the first nine months, indicating healthy cash generation.
- 7IDEXX has sufficient liquidity, with $104.0 million in cash and cash equivalents and $619.1 million in available borrowing capacity under its credit facility as of September 30, 2019.